Economic evaluation of a Decision Support Tool to guide intensity of mental health care in general practice: the Link-me pragmatic randomised controlled trial

Mary Lou Chatterton1,2*, Meredith Harris3,4, Philip Burgess3, Susan Fletcher5, Matthew J. Spittal6, Jan Faller1, Victoria J. Palmer4,5, Patty Chondros4,5, Bridget Bassilios6, Jane Pirkis4,6, Jane Gunn4,5 and Cathrine Mihalopoulos1,2

Abstract

Background: This paper reports on the cost-effectiveness evaluation of Link-me – a digitally supported, systematic approach to triaging care for depression and anxiety in primary care that uses a patient-completed Decision Support Tool (DST).

Methods: The economic evaluation was conducted alongside a parallel, stratified individually randomised controlled trial (RCT) comparing prognosis-matched care to usual care at six- and 12-month follow-up. Twenty-three general practices in three Australian Primary Health Networks recruited 1,671 adults (aged 18 – 75 years), predicted by the DST to have minimal/mild or severe depressive or anxiety symptoms in three months. The minimal/mild prognostic group was referred to low intensity services. Participants screened in the severe prognostic group were offered high intensity care navigation, a model of care coordination. The outcome measures included in this evaluation were health sector costs (including development and delivery of the DST, care navigation and other healthcare services used) and societal costs (health sector costs plus lost productivity), psychological distress [Kessler Psychological Distress Scale (K10)] and quality adjusted life years (QALYs) derived from the EuroQol 5-dimension quality of life questionnaire with Australian general population preference weights applied. Costs were valued in 2018–19 Australian dollars (A$).

Results: Across all participants, the health sector incremental cost-effectiveness ratio (ICER) of Link-me per point decrease in K10 at six months was estimated at $1,082 (95% CI $391 to $6,204) increasing to $2,371 (95% CI $191 to Dominated) at 12 months. From a societal perspective, the ICER was estimated at $1,257/K10 point decrease (95% CI Dominant to Dominated) at six months, decreasing to $1,217 (95% CI Dominant to Dominated) at 12 months. No significant differences in QALYs were detected between trial arms and the intervention was dominated (less effective, more costly) based on the cost/QALY ICER.

Conclusions: The Link-me approach to stepped mental health care would not be considered cost-effective utilising a cost/QALY outcome metric commonly adopted by health technology assessment agencies. Rather, Link-me showed...
Background
In Australia, common mental health problems are initially diagnosed and treated by general practitioners (GPs) [1]; however, under- and over-treatment is common. Australian mental health reforms have promoted stepped care to improve the efficiency and quality of mental health care. Evidence suggests that stepped care can be effective for the treatment of depressive and anxiety disorders [2, 3]; few studies have explored the value for money credentials of stepped care approaches for the treatment of anxiety and depression in primary care settings [3].

The Link-me approach to stepped care comprises a patient-completed digital Decision Support Tool (DST) to predict the severity of depressive and anxiety symptoms in three months’ time, support individuals to identify their mental health treatment priorities, and deliver prognosis-based treatment recommendations.

In a pragmatic, stratified randomised controlled trial (RCT), the Link-me intervention resulted in greater reductions in psychological distress at six months over usual care[4]. This paper reports on the economic evaluation incorporated in the RCT [5].

Methods
The Link-me RCT was conducted within 23 general practices in three Australian states (New South Wales, Victoria, Queensland) across metropolitan, outer metropolitan and regional locations in collaboration with three Primary Health Networks (PHNs). PHNs are not-for-profit companies commissioning health services in 31 geographically defined areas throughout Australia [6]. The study protocol and analysis plan for clinical and economic outcomes are described in full elsewhere [4, 5].

Briefly, adults attending a participating general practice for any reason were invited to complete an eligibility screening tool and the DST (Supporting Information, section S1) on a tablet device in the waiting room. Eligible patients (ages 18–75 years; proficient in English; providing a phone number and email address; having a Medicare card; reporting current anxiety or depression symptoms or use of medication for mental health) were classified into three prognostic groups. Participants categorised into the minimal/mild and severe groups were individually randomised to the intervention or control group. Participants classified as minimal/mild and allocated to the intervention group were offered a selection of low intensity treatment options available through local in-person services, online, by telephone or mobile app. The recommended options were viewed on the tablet immediately after completing the DST and a copy was emailed to participants including links to the relevant services. The severe prognostic group allocated to the intervention were offered care navigation, a model of clinical care coordination informed by the principles of collaborative care and motivational interviewing. Participants could receive up to eight contacts with a trained care navigator to develop and implement a structured care plan to address priorities they identified in the DST. Participants could also access additional care package funding, through the participating PHNs, to support service access when cost was a barrier to care. Participants randomised to the control group for both minimal/mild and severe prognostic groups received advice to discuss any mental health concerns with their GP. The moderate group were excluded from the study based on the availability of mental health service offerings appropriate to this level of need [7].

Costs
A health sector perspective was adopted as the primary perspective for the economic evaluation with a secondary analysis from a partial societal perspective. Health sector costs included the costs of implementing the Link-me intervention and of other health services used by participants during the trial. Partial societal costs included all health sector costs plus the cost of self-reported productivity losses (Supporting Information, Table S1).

A micro-costing approach was used to estimate the cost of the Link-me intervention and included the resources required for screening, the delivery of care navigation and care packages (Supporting Information, Table S2). Although the control group was screened as part of the study, screening costs were not assigned to this group as screening is not reflective of usual care.

Information on health service use was captured through a self-report resource use questionnaire (RUQ) completed by all participants at six and 12-month follow-ups. The RUQ incorporated questions about the number

Trial registration: Australian and New Zealand Clinical Trials Registry, ANZCTR 12617001333303.

Keywords: Economic evaluation, Cost-effectiveness, Mental health, Primary Care, Randomised controlled trial, Care navigation
and type of services accessed (namely, GP, psychologist, psychiatrist, emergency department visits, hospital admissions), medication use, time absent from paid and unpaid work, and days working at reduced capacity while at paid work (presenteeism) due to mental health problems. Standard Australian unit costs were applied (Supporting Information, section S3). Participants were also asked for consent for the study team to access their Medicare Benefits Schedule (MBS) and Pharmaceutical Benefits Scheme (PBS) data. This administrative data provides accurate cost data for government funded health care services and medications.

All costs are presented in 2018–19 Australian dollars (A$). Discounting was not applied as the time horizon was 12 months.

Health outcomes

Self-report outcome measures were administered at baseline, six-month and 12-month follow-ups. The primary outcome measure was the Kessler Psychological Distress (K10) scale [8] at the six-month follow-up. The K10 was used as an outcome measure in economic analyses. Since lower K10 scores indicate less psychological distress (and a negative change score therefore represents a positive outcome), change in K10 was multiplied by -1 to aid interpretation. The Patient Health Questionnaire 9-item version (PHQ-9) [9], Generalised Anxiety Disorder scale (GAD-7) [10] and EuroQol 5-dimension quality of life questionnaire (EQ-5D-5L) [11] were secondary self-report outcome measures. The EQ-5D-5L was used to measure participants’ preference-based health-related quality of life, and Australian general population preference weights were applied to calculate utility values at each time point [12]. Quality-adjusted life years (QALYs) were calculated from the EQ-5D-5L utility values using the area-under-the-curve (AUC) method [13]. QALYs are the preferred outcome metric in Australia, used by health technology assessment agencies such as the Medical Services Advisory Committee, due to their inherent value for money connotations. An implicit threshold of $50,000 per QALY gained has been used for an intervention to be considered cost-effective, and $28,033 per QALY gained is an additional threshold based on contemporary empirical results [14, 15].

Statistical analysis

Statistical analyses were conducted using Stata 15 (College Station, Texas, USA). Base case analyses were conducted on an intention-to-treat (ITT) basis. All enrolled participants who completed a baseline assessment were included; however, 63% of participants were missing cost data and 60% were missing QALYs over 12-month follow-up. To address this, missing cost and outcome data were generated using 50 imputed datasets. Imputed values were estimated using variables for randomisation group, age, gender, baseline K10, PHQ-9, GAD-7 and stratified by prognostic group.

The mean difference in costs from both health sector and societal perspectives were estimated using generalised linear models (GLM) with the gamma family and log link. The mean difference between the intervention and control groups in the change in K10 scores from baseline to six and 12-month follow-ups were estimated using multiple linear regression. The difference in mean QALYs between trial arms was estimated using a GLM with the Gaussian family and identity link. All regression and GLM models were estimated with and without adjustment for several baseline covariates specified a priori (prognostic group and baseline K10 score) [5, 16]. Pre-specified subgroup analyses were conducted across prognostic groups.

Incremental cost-effectiveness ratios (ICERs) were calculated as the difference in mean costs between the intervention and control groups divided by the difference in mean outcome (change in K10 score, QALYs) by study perspective (health sector and societal). A nonparametric bootstrap with 1,000 iterations from the multiple imputed data was undertaken to estimate 95% confidence intervals (95% CI) around each ICER. The resulting iterations were also used to construct cost-effectiveness planes.

A series of sensitivity analyses explored the effects of: analysing complete cases only, including general practice as a covariate, varying the cost of care navigation sessions to account for efficiencies that may be achieved over time; applying the United Kingdom value set for the EQ-5D-5L [17], and using individual level MBS/PBS data to estimate resource use.

Results

Randomised trial

24,616 patients were invited to complete the eligibility screening survey, with 1,671 consenting participants in the trial; 830 classified by the DST into the minimal/mild group and 841 into the severe group (Supporting information, Figure S1). Participants across both trial groups were clinically and demographically similar within prognostic groups and overall (Supporting information, Table S3).

Costs

The average health sector cost per person invited to complete the screening phase was estimated at $7.34. The cost of care navigators was estimated at $1,144 per participant in the severe prognostic group randomised to the intervention (Supporting information, Table S3). Care package funding was provided to 112 participants.
allocated to care navigation, at an average cost of $669 per care package recipient (Supporting information Table S4).

Intervention group participants reported significantly more use of mental health nurses (9.4% vs 5.4%) and psychologists (44.1% vs 35.5%) than the comparison group (Supporting information Table S5). The intervention group also reported significantly more days off from unpaid work in the 12 months since trial enrolment (50 vs. 39 days; Supporting information Table S6).

When averaged across all participants, health sector costs were significantly higher among those in the intervention than the control group, at six and 12-month follow-up (Table 1). The adjusted mean difference in health sector costs between groups was $24 (95% CI 9 to 44) at six months increasing to $50 (95% CI 10 to 102) at 12 months. Similarly, for the severe prognostic group, the adjusted mean difference was $340 at six-months (95% CI 126 to 644) increasing to $645 (95% CI -1.835 to 3.057) at 12 months, but both differences were non-significant.

**Health outcomes**

The difference between the intervention and control groups in mean K10 score reduction at six months was significant across all participants (mean difference -0.88 95% CI -1.66 to -0.11 p = 0.03) and for the severe group (mean difference -1.92 95% CI -3.16 to -0.67 p = 0.003). At 12 months the differences were non-significant across all participants (mean difference -0.55 95% CI -1.39 to 0.30, p = 0.21) and the severe group (mean difference -1.24 95% CI -2.53 to 0.05, p = 0.06; Supporting Information, Table S8).

---

**Table 1** Health sector costs, including intervention costs, according to trial arm, in total sample and stratified by prognostic group

|                      | All participants | p value | Minimal/mild prognostic group | p value | Severe prognostic group | p value |
|----------------------|------------------|---------|-------------------------------|---------|-------------------------|---------|
| **Comparison, n**    | 837              | 416     | 421                           |         |                         |         |
| **Intervention, n**  | 834              | 414     | 420                           |         |                         |         |
| **6 months**         |                  |         |                               |         |                         |         |
| Mean cost (SD) [1]   |                  |         |                               |         |                         |         |
| Comparison           | $1,247 (4,473)   |         | $304 (1,045)                  |         | $2,178 (6,057)          |         |
| Intervention         | $2,231 (6,716)   |         | $429 (1,150)                  |         | $4,006 (8,984)          |         |
| Mean difference, Coef. (95% CI) |          |         |                               |         |                         |         |
| Primary analysis [2] | $24 (9 to 44)    | p < 0.0001 | $28 (-5 to 79)               | 0.106   | $340 (126 to 644)      | p < 0.0001 |
| Sensitivity analysis [3] | $20 (6 to 40)   | 0.002   | $20 (-4 to 60)               | 0.108   | $227 (45 to 514)       | 0.009   |
| Sensitivity analysis [4] | $24 (7 to 46)   | 0.002   | $17 (-2 to 50)               | 0.092   | $320 (94 to 669)       | 0.002   |
| Sensitivity analysis [5] | $23 (9 to 42)   | p < 0.0001 | $29 (-3 to 78)               | 0.078   | $287 (96 to 554)       | 0.001   |
| **12 months**        |                  |         |                               |         |                         |         |
| Mean cost (SD) [1]   |                  |         |                               |         |                         |         |
| Comparison           | $2,787 (9,879)   |         | $640 (1,801)                  |         | $4,908 (13,498)        |         |
| Intervention         | $3,871 (12,178)  |         | $991 (2,448)                 |         | $6,710 (16,476)        |         |
| Mean difference, Coef. (95% CI) |          |         |                               |         |                         |         |
| Primary analysis [2] | $50 (10 to 102)  | 0.011   | $59 (6 to 134)                | 0.025   | $645 (-152 to 1,818)   | 0.128   |
| Sensitivity analysis [3] | $31 (9 to 64)   | 0.003   | $31 (-15 to 114)             | 0.108   | $366 (86 to 802)       | 0.005   |
| Sensitivity analysis [4] | $31 (8 to 62)   | 0.003   | $23 (-10 to 82)              | 0.214   | $492 (143 to 1,031)    | 0.002   |
| Sensitivity analysis [5] | $48 (8 to 99)   | 0.014   | $59 (9 to 131)               | 0.018   | $538 (-219 to 1,651)   | 0.19    |
| Sensitivity analysis [6] | $1 (-26 to 47)  | 0.974   | -3 (.39 to 59)               | 0.911   | $242 (-1,261 to 3,673) | 0.822   |

SD Standard deviation, Coef. Estimated coefficient, CI Confidence interval

[1] Estimated using multiple imputation. [2] Mean for intervention arm minus mean for comparison arm estimated using generalized linear models (gamma family, log link) adjusted for baseline K10 (all models) and prognostic group (model with all participants only). Estimated using multiple imputation. [3] Sensitivity analysis using complete cases only using generalized linear models (gamma family, log link) adjusted for baseline K10 (all models) and prognostic group (model with all participants only). [4] Same as [3] but adjusted for general practice. [5] Sensitivity analysis where care navigators spent 50% of time on care navigation. Data was multiply imputed prior to analysis. [6] Sensitivity analysis using participants with Medicare Benefits Schedule and Pharmaceutical Benefits Scheme data adding covariates of sex and holding a health care card. Only includes 466 participants providing consent to this data (n = 238 in comparison group, n = 228 in Intervention group).
There were no significant differences in EQ-5D-5L utility values (Supporting Information, Table S5) or QALYs (Table 3) between the intervention and control groups, across all participants at either six or 12-month follow up. In subgroup analysis, the minimal/mild prognostic group had a lower average utility for the intervention group at 12 months (mean difference -0.04 95% CI -0.07 to -0.00, \( p = 0.03 \)).

**Cost-effectiveness**

The incremental health sector cost per point decrease in K10 score at six months across all participants was $1,082 (95% CI 391 to 6,204) increasing to $2,371 (95% CI 191 to Dominated) at 12 months (Table 4). From the societal perspective, the cost per point decrease in K10 score at six months was estimated at $1,257 (95% CI Dominant to Dominated), and $1,217 (95% CI Dominant to Dominated) at 12 months. In the minimal/mild prognostic group the cost per point decrease in K10 indicated that the intervention was dominated by the comparison group from both the health sector and societal perspectives. Dominated means that the costs were higher and the mean difference in outcome was negative, in this case the K10 score indicated worse symptoms in the intervention compared to the control group, although the difference was non-significant. Figures 1 and 2 are cost-effectiveness planes providing visual representation of the cost-effectiveness result at six and 12 months.

For the severe prognostic group, the estimated incremental health sector cost per point decrease in K10 score was estimated at $860 (95% CI 366 to 2320) at six months increasing to $1,326 (95% CI 28 to 8361) at 12 months. From the societal perspective the six-month ICER was estimated at $776 per point improved on the K10, decreasing to $479 (95% CI Dominant to 8539) at 12 months.

The lack of a significant difference in QALYs between the intervention and comparison groups from baseline to six-month or 12-month follow-ups, combined with significantly higher health sector costs resulted in Link-me...
Table 3  Quality adjusted life years (QALYs) calculated from EQ-SD-5L preference-based utility values, according to trial arm, in total sample and stratified by prognostic group

|                      | All participants | Minimal/mild symptom group | Severe symptom group |
|----------------------|------------------|-----------------------------|----------------------|
|                      | p value          | p value                     | p value              |
| Comparison, n        | 837              | 416                         | 421                  |
| Intervention, n      | 834              | 414                         | 420                  |
| Baseline to 6 months |                  |                             |                      |
| Mean QALYs (SD) [1]  |                  |                             |                      |
| Comparison           | 0.610 (0.281)    | 0.776 (0.162)               | 0.445 (0.275)        |
| Intervention         | 0.606 (0.285)    | 0.776 (0.163)               | 0.439 (0.282)        |
| Mean difference, Coef. (95% CI) |              |                             |                      |
| Primary analysis [2] | -0.004 (-0.024 to 0.017) | 0.733                     | -0.004 (-0.025 to 0.018) | 0.737 | -0.002 (-0.036 to 0.033) | 0.922 |
| Sensitivity analysis [3] | -0.002 (-0.027 to 0.023) | 0.883                     | 0.000 (-0.026 to 0.025) | 0.991 | -0.002 (-0.044 to 0.040) | 0.927 |
| Sensitivity analysis [4] | -0.002 (-0.026 to 0.023) | 0.901                     | 0.001 (-0.025 to 0.026) | 0.967 | -0.002 (-0.044 to 0.040) | 0.931 |
| Sensitivity analysis [5] | 0.004 (-0.010 to 0.017) | 0.620                     | -0.001 (-0.016 to 0.013) | 0.840 | 0.009 (-0.013 to 0.031) | 0.407 |
| Sensitivity analysis [6] | -0.002 (-0.018 to 0.013) | 0.782                     | 0.000 (-0.015 to 0.012) | 0.900 | -0.001 (-0.029 to 0.026) | 0.926 |
| Baseline to 12 months |                  |                             |                      |
| Mean QALYs (SD) [1]  |                  |                             |                      |
| Comparison           | 0.621 (0.287)    | 0.779 (0.173)               | 0.465 (0.287)        |
| Intervention         | 0.613 (0.282)    | 0.772 (0.166)               | 0.456 (0.294)        |
| Mean difference, Coef. (95% CI) |              |                             |                      |
| Primary analysis [2] | -0.008 (-0.029 to 0.014) | 0.481                     | -0.001 (-0.033 to 0.013) | 0.400 | -0.004 (-0.041 to 0.033) | 0.831 |
| Sensitivity analysis [3] | -0.002 (-0.027 to 0.023) | 0.883                     | -0.000 (-0.026 to 0.025) | 0.991 | -0.002 (-0.044 to 0.040) | 0.927 |
| Sensitivity analysis [4] | -0.002 (-0.026 to 0.023) | 0.901                     | 0.001 (-0.025 to 0.026) | 0.967 | -0.002 (-0.044 to 0.040) | 0.931 |
| Sensitivity analysis [5] | 0.004 (-0.010 to 0.017) | 0.620                     | -0.001 (-0.016 to 0.013) | 0.840 | 0.009 (-0.013 to 0.031) | 0.407 |
| Sensitivity analysis [6] | -0.006 (-0.022 to 0.011) | 0.506                     | -0.006 (-0.020 to 0.008) | 0.414 | -0.003 (-0.033 to 0.026) | 0.827 |

SD Standard deviation, Coef. Estimated coefficient, CI Confidence interval

[1] Estimated using multiple imputation. [2] Mean for intervention arm minus mean for comparison arm estimated using generalized linear models (Gaussian family, identity link) adjusted for baseline K10 (all models) and prognostic group (model with all participants only). Estimated using multiple imputation. [3] Sensitivity analysis using complete cases only using generalized linear models (Gaussian family, identity link) adjusted for baseline K10 (all models) and prognostic group (model with all participants only). [4] Same as [3] but adjusted for general practice. [5] Sensitivity analysis using multiple imputation adjusted for baseline EQ-SD utility value. [6] Sensitivity analysis using utility values calculated with the UK value set for the EQ-SD-5L, estimated using multiple imputation and generalized linear models (Gaussian family, identity link) adjusted for baseline K10 (all models) and prognostic group (model with all participants only).

Table 4  Incremental cost-effectiveness ratios using ITT data (imputed) and based on unadjusted cost differences

|                      | All participants | Minimal/mild prognostic group | Severe prognostic group |
|----------------------|------------------|-----------------------------|----------------------|
|                      | n = 1671         | n = 830                     | n = 841              |
| Health sector perspective |                  |                             |                      |
| ICER (95% CI)        |                  |                             |                      |
| 6 months             | $1,082/point improvement on K10 (391 to 6,204) | Dominated | $860/point improvement on K10 (366 to 2320) |
| 12 months            | $2,371/point improvement on K10 (191 to Dominated) | Dominated | $1,326/point improvement on K10 (28 to 8361) |
| Societal perspective |                  |                             |                      |
| ICER (95% CI)        |                  |                             |                      |
| 6 months             | $1,257/point improvement on K10 (Dominant to Dominated) | Dominated | $776/point improvement on K10 (82 to 2551) |
| 12 months            | $1,217/point improvement on K10 (Dominant to Dominated) | Dominated | $479/point improvement on K10 (Dominant to 8539) |

CI Confidence interval, ICER Incremental cost-effectiveness ratio, Dominated Greater costs and less benefit than the comparator, Dominant Less costs and greater benefits than the comparator. ICERs and CIs were estimated based on 1,000 bootstrap samples of the multiply imputed data.
being dominated. Therefore, incremental cost-utility ratios were not calculated.

**Sensitivity analyses**

The results were generally robust in sensitivity analyses. Exceptions were the non-significant differences in 12-month health sector costs when using MBS/PBS data and changes to significance in complete case analyses for prognostic sub-groups.

**Discussion**

This is the first economic evaluation of a digital platform designed to predict the severity of symptoms and coordinate care for people with depression or anxiety in primary care. Our results suggest that Link-me was associated with additional health sector and societal costs but resulted in achieving additional improvement in mental health symptoms. Incremental costs were highest for the severe prognostic group which also achieved the largest incremental improvement in mental health symptom scores.

Given the time-limited nature of the trial, reported costs may be considered the upper estimate of the true costs associated with delivering care navigation (i.e., training and development) and would likely reduce over time once the intervention became established. The Link-me intervention was most likely not running at full economic efficiency because the rollout of the actual process of care navigation was being fine-tuned with the cost of likely learning effects being incurred. If the learning effects were finalised and Link-me was running at steady state, the throughput of participants would be increased, leading to reductions in average cost per person and contact.

Link-me is a novel approach; therefore, published evaluations of directly comparable interventions are lacking. An economic evaluation of the precursor digital platform to Link-me used to manage the treatment of people with depression found it to be dominant (more effective
and less costly) over usual care from both health sector and societal perspectives [18]. It utilised the Assessment of Quality of Life-8D (AQoL-8D) questionnaire [19] to measure utility values and calculate QALYs in contrast to the current evaluation using the EQ-5D-5L. Despite improvements in mental health symptom scores measured with the K10 in the current evaluation, no significant differences were found between groups on the EQ-5D-5L utility scores or QALYs. Economic analyses of collaborative care interventions for treating depression in primary care found mixed results for cost-utility analyses [20, 21]. Studies using the Short Form quality of life measure detected significant differences in QALYs, while those using the EQ-5D found negative or non-significant incremental QALYs [20]. This may reflect lower sensitivity of the EQ-5D to changes in quality of life resulting from improvement in mental health symptoms, despite previous studies indicating that most multi-attribute utility instruments can discriminate between differing levels of symptom severity for people with depression [22]. Link-me provided statistically significant improvement in K10 scores over existing care at six-month follow up, however the mean difference did not reach the prespecified minimal clinically relevant difference of 2.4 points (equivalent to a standardised mean difference of -0.3). However, half of the participants allocated to the Link-me intervention did not accept the offer to engage in care navigation. When a complier average causal effect analysis was undertaken to assess the magnitude of change in K10 scores associated with engagement in the different steps of care navigation, the intervention effect size increased and led to clinically meaningful differences [4]. This suggests that there is an opportunity to optimise the Link-me intervention to improve engagement potentially leading to improved clinical outcomes.

Average health sector and societal costs across all participants for both the Link-me and control groups were higher than reported in previous economic evaluations of stepped and collaborative care interventions for people with depression [3, 20, 21]. The addition of anxiety symptoms to the prognostic model of the DST may have contributed to this result. Previous research found...
that health sector and productivity costs for comorbid depression and anxiety were significantly higher than either diagnosis alone [23]. Another explanation is that there was increased time missed from work since study participants in both randomised groups were seeking additional treatment for their mental health concerns.

The Link-me intervention was hypothesised to be cost-effective through triaging participants in the minimal/mild prognostic group to low intensity services associated with lower costs and offsetting the increased costs of care in the severe prognostic group. However, participants in the minimal/mild prognostic group who were offered low intensity services had a significantly higher average mean health sector cost at 12-month follow-up than their usual care counterparts, in part due to their greater use of psychology services. This may be due to the pragmatic nature of this real-world trial since we could not limit access to more intensive forms of care. Participants in the Link-me group utilised psychological services at a similar rate to the comparison group among the minimal/mild prognostic group (25% vs. 19% comparison). The feedback and opportunity for reflection provided by the Link-me DST may have prompted increased help-seeking through psychologists, in preference to the suggested low-intensity options, partially accounting for the higher costs observed.

Strengths and limitations
The relatively large sample size and embedding of this economic evaluation in a pragmatic RCT engenders confidence in the results. The number and diversity of general practices recruiting study participants suggests that the results are generalisable to similar Australian practices.

This study is also subject to limitations. The use of a self-report measure of health care utilisation and lost productivity are subject to recall bias. However, this would affect both groups in the trial, and previous studies have demonstrated the validity of self-reported RUQs [24]. The sensitivity analyses conducted using accurate administrative data (MBS/PBS) produced results which differed from the primary analyses: namely smaller, non-significant mean differences in health sector costs between the Link-me and control groups. It is important to note that an additional consent was required to access participants’ MBS/PBS data, and only 28% of participants provided this consent, thus limiting the usefulness of this sensitivity analysis.

There was also a high volume of missing data (63.2% control group, 56% Link-me at 12-month follow-up) which may affect the validity of the results. Efforts were made in the design and conduct of the trial to minimise the loss of data, and the analytic approach followed published recommendations for managing missing data [25, 26]. The additional sensitivity analysis to evaluate the effect of imputed missing data did not alter the interpretation of the findings. However, it is unclear if the results would change if all participants completed every follow-up assessment.

Conclusions
The Link-me approach to stepped mental health care would not be considered cost-effective utilising the cost/QALY outcome metric commonly used by health technology assessment agencies. Link-me could be viewed as trending toward cost-effectiveness by providing improvement in mental health symptoms, assessed by the K10, for additional cost. Given the Productivity Commission’s recommendation for a national digital mental health platform to support a person-centred approach to mental health care in Australia [27], Link-me should be appraised for this important function.

Abbreviations
A$: Australian dollars; CI: Confidence Interval; GLM: Generalised linear model; ICER: Incremental cost effectiveness ratio; ITT: Intention-to-treat; MBS: Medicare Benefits Schedule; PBS: Pharmaceutical Benefits Scheme; QALYs: Quality Adjusted Life Years; RCT: Randomised controlled trial; RUQ: Resource use questionnaire.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12875-022-01839-z.

Acknowledgements
We are grateful to the many dedicated GPs, practice staff, and general practice patients who took part in Link-me. We also thank the regional trial coordinators at participating PHNs, care navigators, recruitment and survey follow-up research assistants who assisted with trial establishment, intervention delivery, and data collection. Trial coordination within the University of Melbourne was initially provided by Anna Wood. We also acknowledge the contribution of Strategic Data Ltd in building the Link-me online portal and providing ongoing support and maintenance. Finally, we thank the Evaluation Advisory Group for their advice throughout the trial; the Expert Working Group for their input into the Decision Support Tool; and the Department of Health and North Western Melbourne, Brisbane North, and North Coast PHNs for their input into the development and implementation of the trial protocol. We acknowledge the provision of Medicare Benefits Schedule and Pharmaceutical Benefits Scheme data by Services Australia under reference number MB8420.

Authors’ contributions
CM conceived the economic evaluation design within the randomised controlled trial. JG conceived of the trial, initiated the trial design, and gained funding. MLC conducted the economic evaluation analyses and drafted the manuscript with assistance from JF. SF managed the day-to-day running of the trial and provided detailed input on the manuscript. JG, JP, CM, PB, MH, BB, VP, MS, and SF are funding holders. All authors interpreted the data, contributed intellectual content, and approved the submitted manuscript.
Funding
Australian Government Department of Health.

Availability of data and material
Reasonable requests for de-identified data and analytical code will be consid-
ered and should be submitted to jgunn@unimelb.edu.au. Release of data will be
subject to approval by relevant ethics and/or monitoring committees and
completion of data access agreement form(s).

Declarations

Ethics approval and consent to participate
The trial and economic evaluation was performed in accordance with the Aus-
tralian National Statement on Ethical Conduct in Human Research (2007) and
the Declaration of Helsinki. Informed consent to participate in the trial was
obtained from all participants prior to randomisation. The study procedures
and informed consent was approved by the University of Melbourne Human
Research Ethics Committee (application ID: 1749832) and the Deakin Univer-
sity Human Research Ethics Committee (application ID: 2018–084).

Consent for publication
Not applicable.

Competing interests
MH reports personal fees from RAND Corporation outside the submitted work.
The remaining authors declare that they have no competing interests.

Author details
1 School of Public Health and Preventive Medicine, Monash University, Level 4, 553 St Kilda Road, Melbourne, VIC 3004, Australia. 2 Deakin Health Economics, Deakin University, Institute for Health Transformation, Geelong, Australia. 3 School of Public Health, The University of Queensland, Brisbane, Australia. 4 The ALIVE National Centre for Mental Health Research Translation, The University of Melbourne, Melbourne, Australia. 5 Department of General Practice, Melbourne Medical School, The University of Melbourne, Melbourne, Australia. 6 Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Australia.

Received: 1 September 2021 Accepted: 26 August 2022
Published online: 16 September 2022

References
1. Burgess PM, Pirks JE, Slade TN, Johnston AK, Meadows GN, Gunn JM. Ser-
vice use for mental health problems: findings from the 2007 National Survey of
Mental Health and Wellbeing. Aust N Z J Psychiatry. 2009;43(2):115–22.
2. van Straten A, Hill J, Richards DA, Cuijpers P. Stepped care treatment delivery
for depression: a systematic review and meta-analysis. Psychol Med.
2015;45(2):231–46.
3. Ho FY, Yeung WF, Ng TH, Chan CS. The efficacy and cost-effectiveness of
stepped care prevention and treatment for depressive and/or anxiety
disorders: a systematic review and meta-analysis. Sci Rep. 2016;6:29281.
4. Fletcher S, Spittal MJ, Chondros P, Palmer VJ, Chatterton ML, Densley K, et al.
Clinical efficacy of a decision support tool (Link-me) to guide intensity of
mental health care in primary practice: a pragmatic stratified randomised
controlled trial. The Lancet Psychiatry. 2021;8(3):202–14.
5. Fletcher S, Chondros P, Palmer VJ, Chatterton ML, Spittal MJ, Mihalopoulos
C, et al. Link-me: Protocol for a randomised controlled trial of a systematic
approach to stepped mental health care in primary care: Contemp Clin
Trials. 2019;76:63–75.
6. Australian Government. Department of Health. Fact Sheet: Primary Health
Networks 2018. Available from: https://www1.health.gov.au/internet/main/
publishing.nsf/Content/Fact-Sheet-Primary-Health-Networks+
7. Australian Government. Department of Health. Fact Sheet for allied health
professionals: Better Access to psychiatrists, psychologists and general
practitioners through the MBS (Better Access) initiative 2019. Available from:
https://www.health.gov.au/sites/default/files/documents/2020/09/better-
access-fact-sheet-professionals-better-access-fact-sheet-professionals.pdf.
8. Kessler RC, Andrews G, Colpe LJ, Hiripi E, Mroczek DK, Normand SLT, et al.
Short screening scales to monitor population prevalences and trends in
non-specific psychological distress. Psychol Med. 2002;32(6):959–76.
9. Kroenke K, Spitzer RL, Williams JBW. The PHQ-9: validity of a brief depression
severity measure. J Gen Intern Med. 2001;16(9):606–13.
10. Spitzer RL, Kroenke K, Williams JBW, Lowe A. A brief measure for
assessing generalized anxiety disorder. The GAD-7. Arch Intern Med.
2006;166(10):1092–7.
11. Herdman M, Gudex C, Lloyd A, Janssen MF, Kind P, Parkin D, et al. Develop-
ment and preliminary testing of the new five-level version of EQ-5D:
EQ-5D-5L. Qual Life Res. 2011;20(3):519–26.
12. Viney R, Norman R, Brazier J, Cronin P, King JT, Ratcliffe J, et al. An Austral-
ian discrete choice experiment to value eq-5d health states. Health Econ.
2014;23(6):729–42.
13. Blick HA, Doshi JA, Sonnad SS, Polsky D. Economic Evaluation in Clinical
Trials. Oxford: Oxford University Press, 2014.
14. Carter R, Voi T, Moodie M, Habby M, Magnus A, Mihalopoulos C. Priority
setting in health: origins, description and application of the Australian
Assessing Cost-Effectiveness Initiative. Exp Rev Pharmacoecon Outcomes
Res. 2008;8(6):593–617.
15. Edney LC, Haji Ali Afzali H, Cheng TC, Karmon J. Estimating the incremen-
tal cost-effectiveness ratio for the Australian health system. Pharma-
coeconomics. 2018;36(2):239–52.
16. Spittal MJ, Chondros P, Mihalopoulos C, Fletcher S, Chatterton ML, Densley
K, et al. Statistical analysis plan for Link-me: a randomised controlled trial
of a systematic approach to stepped mental health care in primary care 2019
[cited 2019 July]. Available from: https://www.anzctr.org.au/Trial/Registra-
ton/TrialReview.aspx?id=373686.
17. Ramos-Gotli JM, Pinto-Prades JL, Oppe M, Cabasés JM, Serrano-Aguilar P,
Rivero-Arias O. Valuation and modeling of EQ-5D-5L health states using a
hybrid approach. Med Care. 2017;55(7).
18. Lee YY, Mihlaopoulos C, Chatterton ML, Fletcher J, Chondros P, Densley K,
et al. Economic evaluation of the Target-D platform to match depression
management to severity prognosis in primary care: A within- trial cost-utility
analysis. PLOS ONE. 2022;17(5):e0268948.
19. Richardson J, Lezzi A, Khan MA, Maxwell A. Validity and reliability of the
Assessment of Quality of Life (AQoL)-8D multi-attribute utility instrument.
The patient. 2014;7(1):85–96.
20. Grochteldt T, Brettschneider C, Wegener A, Watzke B, Riedel-Heller S, Härter
M, et al. Cost-effectiveness of collaborative care for the treatment of depres-
sive disorders in primary care: a systematic review. PLoS ONE. 2015;10(5):
e0123078.
21. vans C, Rittenbach K, Souri S, Silverstone PH. Cost-effectiveness analysis of
a randomized study of depression treatment options in primary care sug-
gests stepped-care treatment may have economic benefits. BMC Psychiatry.
2019;19(1):240.
22. Mihalopoulos C, Chen G, Iezzi A, Khan M, Richardson J. Assessing outcomes
for cost-utility analysis in depression: Comparison of five multi-attribute
utility instruments with two depression-specific outcome measures. Br J
Psychiatry. 2014;205(3):380–7.
23. Lee YC, Chatterton ML, Magnus A, Mohebbi M, Le K, Mihalopoulos C. Cost
of high prevalence mental disorders: Findings from the 2007 Australian
National Survey of Mental Health and Wellbeing. Aust N Z J Psychiatry.
2017;51(12):1198–211.
24. Leggett LE, Khadaroo RG, Hillery K, Lorenzetti DL, Hanson H, Wagg
A, et al. Measuring resource utilization: a systematic review of validated self-
reported questionnaires. Medicine (Baltimore). 2016;95(10):e2759-e.
25. van C, Rittenbach K, Souri S, Silverstone PH. Cost-effectiveness analysis of
a randomized study of depression treatment options in primary care sug-
gests stepped-care treatment may have economic benefits. BMC Psychiatry.
2019;19(1):240.
26. Mihalopoulos C, Chen G, Iezzi A, Khan M, Richardson J. Assessing outcomes
for cost-utility analysis in depression: Comparison of five multi-attribute
utility instruments with two depression-specific outcome measures. Br J
Psychiatry. 2014;205(3):380–7.
27. Australian Government. Productivity Commission. Mental health report no.
95, Canberra 2020. Available from: https://www.pc.gov.au/inquiries/compli-
enced/mental-health/report.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub-
lished maps and institutional affiliations.